Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience

This letter to the editor describes myocarditis screening among patients undergoing combination immune checkpoint inhibitor therapy, in light of the consensus document from the Checkpoint Inhibitor Safety Working Group.

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2019-05, Vol.24 (5), p.e196-e197
Main Authors: Lee Chuy, Katherine, Oikonomou, Evangelos K., Postow, Michael A., Callahan, Margaret K., Chapman, Paul B., Shoushtari, Alexander N., Neilan, Tomas G., Fradley, Michael G., Ramanathan, Lakshmi V., Wolchok, Jedd D., Steingart, Richard M., Gupta, Dipti
Format: Article
Language:English
Subjects:
Aged
Humans
Immunotherapy - methods
Letter to the Editor
Melanoma - complications
Melanoma - drug therapy
Middle Aged
Myocarditis - diagnosis
Myocarditis - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This letter to the editor describes myocarditis screening among patients undergoing combination immune checkpoint inhibitor therapy, in light of the consensus document from the Checkpoint Inhibitor Safety Working Group.
ISSN:1083-7159
1549-490X
DOI:10.1634/theoncologist.2019-0040